NO20031851L - Kombinasjon av fenofibrat og koenzym Q10 for behandling av endotelial feilfunksjon - Google Patents

Kombinasjon av fenofibrat og koenzym Q10 for behandling av endotelial feilfunksjon

Info

Publication number
NO20031851L
NO20031851L NO20031851A NO20031851A NO20031851L NO 20031851 L NO20031851 L NO 20031851L NO 20031851 A NO20031851 A NO 20031851A NO 20031851 A NO20031851 A NO 20031851A NO 20031851 L NO20031851 L NO 20031851L
Authority
NO
Norway
Prior art keywords
coenzyme
treatment
combination
fenofibrate
precursor
Prior art date
Application number
NO20031851A
Other languages
English (en)
Other versions
NO20031851D0 (no
NO332260B1 (no
Inventor
Gerald Watts
David Playford
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en
Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of NO20031851D0 publication Critical patent/NO20031851D0/no
Publication of NO20031851L publication Critical patent/NO20031851L/no
Publication of NO332260B1 publication Critical patent/NO332260B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en kombinasjon av en peroksisom- proliferator aktivert reseptor- (PPAR) aktivator og et benzokinon og anvendelse av dem ved behandling og/eller forhindring av lidelserendotel-dysfunksjon, så som kardiovaskulær sykdom, slag og myokardialt infarkt. 1 henhold til en foretrukket utførelsesform av oppfinnelsen er benzokinon eller en forløper derav et ubiquinon eller forløper derav, mer foretrukket, koenzym Qeller en forløper derav og PPAR-aktivatoren er et fibrat eller et tiazolidindion, mer foretrukket fenofibrat.
NO20031851A 2000-10-26 2003-04-24 Preparat omfattende en peroksisom-proliferator aktivert reseptor-(PPAR) aktivator valgt fra et fibrat, et tiazolidindion og et benzokinon valgt fra ubikinon, farmasoytisk preparat omfattende samme samt metode for a fremstille slike, slike preparater for anvendelse i terapi samt anvendelse av slike preparater for behandling av sykdom NO332260B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR1038A AUPR103800A0 (en) 2000-10-26 2000-10-26 Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en) 2001-02-28 2001-02-28 Compositions for the treatment of endothelial dysfunction
PCT/EP2001/012425 WO2002034259A1 (en) 2000-10-26 2001-10-23 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction

Publications (3)

Publication Number Publication Date
NO20031851D0 NO20031851D0 (no) 2003-04-24
NO20031851L true NO20031851L (no) 2003-06-24
NO332260B1 NO332260B1 (no) 2012-08-13

Family

ID=25646491

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031851A NO332260B1 (no) 2000-10-26 2003-04-24 Preparat omfattende en peroksisom-proliferator aktivert reseptor-(PPAR) aktivator valgt fra et fibrat, et tiazolidindion og et benzokinon valgt fra ubikinon, farmasoytisk preparat omfattende samme samt metode for a fremstille slike, slike preparater for anvendelse i terapi samt anvendelse av slike preparater for behandling av sykdom

Country Status (29)

Country Link
US (1) US7410983B2 (no)
EP (1) EP1328266B1 (no)
JP (1) JP4236464B2 (no)
KR (1) KR100862129B1 (no)
CN (1) CN1220488C (no)
AR (1) AR035071A1 (no)
AT (1) ATE316787T1 (no)
AU (1) AU2176502A (no)
BG (1) BG65979B1 (no)
BR (1) BR0114701A (no)
CA (1) CA2426625C (no)
CY (1) CY1105007T1 (no)
CZ (1) CZ301282B6 (no)
DE (1) DE60117046T2 (no)
DK (1) DK1328266T3 (no)
DZ (1) DZ3442A1 (no)
EE (1) EE05281B1 (no)
ES (1) ES2257457T3 (no)
HU (1) HUP0303566A3 (no)
IL (2) IL155524A0 (no)
MA (1) MA25847A1 (no)
MX (1) MXPA03003733A (no)
NO (1) NO332260B1 (no)
PL (1) PL212952B1 (no)
PT (1) PT1328266E (no)
RU (1) RU2003111175A (no)
SK (1) SK287992B6 (no)
TN (1) TNSN01151A1 (no)
WO (1) WO2002034259A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408950B1 (en) 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
US20060052457A1 (en) * 2002-03-11 2006-03-09 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20070225614A1 (en) 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
ES2823728T3 (es) 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
WO2007106912A2 (en) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US20070225606A1 (en) * 2006-03-22 2007-09-27 Endothelix, Inc. Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
US20080081963A1 (en) * 2006-09-29 2008-04-03 Endothelix, Inc. Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
WO2010088378A1 (en) * 2009-01-29 2010-08-05 Levine Joshua D Method of adding botanical agents/dietary supplements to pharmaceutical agents in a pharmacotherapeutic regimen
US8973851B2 (en) * 2009-07-01 2015-03-10 The Procter & Gamble Company Apparatus and methods for producing charged fluid droplets
ES2657940T3 (es) * 2010-03-26 2018-03-07 Emerald Health Pharmaceuticals Inc. Derivados de quinona de cannabinoides
RU2554500C2 (ru) * 2013-09-20 2015-06-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения ишемического инсульта
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
US10881686B2 (en) 2017-10-27 2021-01-05 Zeta Biolongevity, Inc Compositions and methods for treating and preventing proteinuria and endothelial erosion
CN110907407B (zh) * 2019-12-03 2022-02-25 东北石油大学 一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229385A (en) * 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP1034791A1 (en) 1997-11-28 2000-09-13 Nikolai Vasilievich Karsanov Anti-hypoxic and anti-ischemic drug
US6423742B1 (en) * 1999-09-02 2002-07-23 Drake Larson Compositions for reducing vascular plaque formation and methods of using same

Also Published As

Publication number Publication date
SK287992B6 (sk) 2012-09-03
CY1105007T1 (el) 2009-11-04
BR0114701A (pt) 2003-11-18
PL212952B1 (pl) 2012-12-31
CZ301282B6 (cs) 2009-12-30
MA25847A1 (fr) 2003-07-01
EP1328266A1 (en) 2003-07-23
AR035071A1 (es) 2004-04-14
US20040022778A1 (en) 2004-02-05
CA2426625C (en) 2010-06-01
WO2002034259A1 (en) 2002-05-02
JP2004512302A (ja) 2004-04-22
EE200300165A (et) 2003-06-16
DK1328266T3 (da) 2006-06-06
IL155524A0 (en) 2003-11-23
CA2426625A1 (en) 2002-05-02
KR20030055276A (ko) 2003-07-02
BG65979B1 (bg) 2010-08-31
PL361635A1 (en) 2004-10-04
EP1328266B1 (en) 2006-02-01
ATE316787T1 (de) 2006-02-15
DE60117046T2 (de) 2006-09-28
AU2176502A (en) 2002-05-06
NO20031851D0 (no) 2003-04-24
TNSN01151A1 (en) 2005-11-10
MXPA03003733A (es) 2004-10-15
SK5082003A3 (en) 2003-11-04
NO332260B1 (no) 2012-08-13
BG107765A (bg) 2004-02-27
KR100862129B1 (ko) 2008-10-09
IL155524A (en) 2008-08-07
RU2003111175A (ru) 2004-09-10
CN1220488C (zh) 2005-09-28
EE05281B1 (et) 2010-04-15
HK1057340A1 (en) 2004-04-02
US7410983B2 (en) 2008-08-12
CN1471390A (zh) 2004-01-28
PT1328266E (pt) 2006-05-31
HUP0303566A3 (en) 2005-05-30
ES2257457T3 (es) 2006-08-01
DE60117046D1 (de) 2006-04-13
DZ3442A1 (fr) 2002-05-02
HUP0303566A2 (hu) 2004-03-01
JP4236464B2 (ja) 2009-03-11

Similar Documents

Publication Publication Date Title
TNSN01151A1 (en) Compositions for the treatment of endothelial dysfunction
NO20071930L (no) t4Metoder og sammensetninger til behandling av hyperlipidemi.
GB0031103D0 (en) Chemical compounds
ES2193976T3 (es) Composiciones para proporcionar y mantener la energia y la alerta mental.
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
JP2003520232A5 (no)
IL159002A0 (en) Modulators of peroxisome proliferator activated receptors (ppar)
WO1999040904A3 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
NO20041596L (no) Kombinasjon av NSAID og en PDE-4 inbibitor og anvendelse derav til behandling av inflammatorisk tarmsykdom, Chrons sykdom, irritabel tarmsykdom og ulceros kolitt
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
NO981123L (no) Pastaformig vaske- og rengjöringsmiddel
ATE382043T1 (de) Sulfonamid-derivate als ppar-modulatoren
GB0012362D0 (en) Chemical compounds
AP2002002510A0 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their sythesis.
CA2427338A1 (en) Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
DE69824748D1 (de) Pharmazeutische zusammensetzung für die behandlung von enzündlichen darmerkrankungen
MA29246B1 (fr) Derives de dihydroimidazothiazole
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
MXPA02007901A (es) Nodulacion de la formacion de hueso.
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
BR9917248A (pt) Composição detergente contendo umametaloprotease
DE60121804D1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
IS6449A (is) Aðferð til framleiðslu á 5-sýanóþalíði
DE60319033D1 (de) Waschmitteltabletten
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees